:::

詳目顯示

回上一頁
題名:生技專利聯盟模型可行性之探討
書刊名:智慧財產評論
作者:許舜喨 引用關係
作者(外文):Hsu, Shun-liang
出版日期:2010
卷期:8:1
頁次:頁29-86
主題關鍵詞:專利聯盟授權中草藥公平交易Patent poolChinese herbal medicineLicensingPatent pool management committee
原始連結:連回原系統網址new window
相關次數:
  • 被引用次數被引用次數:期刊(1) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:1
  • 共同引用共同引用:51
  • 點閱點閱:25
近年來國外雖已有專利聯盟相關研究,但大多集中在電子產業,我國目前也沒有生技產業專利聯盟出現。本研究以美國、歐盟、日本之專利聯盟制度與我國做比較,設計出適合我國中草藥專利聯盟之管理機制,以中草藥專利聯盟管理委員會為基本架構,進一步依業務類型分為人事、財務、行銷、智財管理以及法務共五個群組,其下再分部作更細微的分工。在明確的組織架構下,便能達到創造、推廣、應用和保護專利聯盟成員之智慧財產權,並建立聯盟成員間技術交流之平台,實現資源共享的目標。本研究以現行中草藥資料庫所得之專利,依用途分為皮膚類、心血管類、抗氧化類、抗癌、肝膽類、治療截癱、肺、記憶力、腎等共24 類。透過假設產品之方法,依照產品所要解決之症狀,從24 種用途別中找出所需專利並作組合,透過聯盟授權平台取得一次性授權,降低授權談判成本,達到整合並活絡中草藥相關專利之目的。從各國及我國對於專利聯盟之規範,可以發現其不必然違反公平交易法,由於專利聯盟常引發之行為包括聯合行為、獨占濫用行為、搭售等行為,可能產生限制競爭或不公平競爭行為而有權利濫用之虞,專利聯盟是否造成限制競爭及不公平競爭必須從專利聯盟之組織行為、架構、運作方式、功能等來判斷。而我國除了有公平交易法之規定外,公平交易委員會亦訂定技術授權協議案件之處理原則,將授權約款類型加以分類,明確定出不違反、違反、可能違反公平交易法事項之具體例示。由於此處理原則並未對專利聯盟作特別規定,僅於符合處理原則之類型才有適用之可能,如能參考如歐盟、日本制訂專屬於專利聯盟之處理原則,在該原則中釐清專利聯盟之概念以及評估原則,將有助於專利聯盟之運作,且能吸引更多人運用專利聯盟,達到資源整合之目的,促進競爭之效益。
The proposed “plurilateral” Anti-Counterfeiting Trade Agreement (ACTA)intends to effectively “re-balance” the rights between intellectual property right (hereinafter as IPR) owners and consumers, as copyright, trademark and even patent holders believe. Yet, once the ACTA goes too far, the multinationals who wish for a double windfall, may be disappointed later when the adverse outcomes follow contrary to their expectations. More specifically, the criminal enforcement provision in the earlier leaked text of the ACTA, makes it clear that the Japan - U.S. joint proposal would like the ACTA to go well beyond cases of commercial counterfeiting and piracy. Arguably, non-commercial activities that take place through internet distribution and information technology such as peer-to-peer (P2P) file sharing would be captured by this provision, which would likely result in unprecedented impacts to an information society in two aspects. First, such proposed ACTA would be inconsistent with Article 61 of the TRIPS Agreement, or, more accurately, has expanded the scope of the TRIPS Agreement; in addition to the clash with the TRIPS Agreement, the ACTA would contradict the Electronic Communications Privacy Act of 1986 (ECPA) and the Digital Millennium Copyright Act (DMCA) as well, owing to the omission of subpoena provisions that protect ISPs from liability of privacy violations. Second, the imposition of criminal sanctions in cases of IP infringements would highly possibly to bring about thefallouts of anti-innovation and anti-competition and thus may not turn out as the ACTA purported, rather, such approach would conversely encourage motivation to piracy and counterfeiting conducts, arising from market forces. As a convincing rebuttal against the criminal enforcement provision in the proposed ACTA, Oberholzer-Gee and Strumpf’s empirical study found that illegal music downloads have had no noticeable effects on the sale of music, contrary to the claims of the recording industry. Stated another way, over-strict criminal sanctions on non-commercial file-sharing users should not be the way to effectively deter infringement; instead, while prosecutions will not stop illegal file trading altogether, what IPR owners need to do, economically, is to reduce infringement enough that they can make a return on their investment. Therefore, this article aims to provide a new paradigm that both re-allocates the marginal costs inherent in the production and distribution of digital content, and lowers enforcement costs burdened on IPR owners, to maintain the equilibrium of IPR holders and the general public.
期刊論文
1.何愛文(200310)。專利聯盟所生競爭法上爭議。公平交易季刊,11(4),1-29。new window  延伸查詢new window
2.Ebersole, T. J.、Guthrie, M. C.、Goldstein, J. A.(2005)。Patent Pools as a Solution to the Licensing Problems of Diagnostic Genetics。Intellectual Property & Technology Law Journal,17(1),6-13。  new window
3.徐雅芬(2005)。中草藥產業現況與趨勢。農業生技產業季刊,1,9-14。  延伸查詢new window
4.莊春發(20010200)。論「足以影響市場功能」的聯合行為。月旦法學,69,42-65。new window  延伸查詢new window
5.Eisenhardt, Kathleen M.(1989)。Building Theories from Case Study Research。Academy of Management Review,14(4),532-550。  new window
6.Grassler, F.、Capria, M. N.(2003)。“Patent pooling: Uncorking a technology transfer bottleneck and creating value in the biomedical research field”。Journal of Commercial Biotechnology,9(2),111-128。  new window
7.黃奕儒(20090305)。台灣中草藥廠商現況調查分析。台灣經濟研究月刊,32(3)=375,54-59。new window  延伸查詢new window
8.和育東(200801)。專利叢林問題與美國專利政策的轉折。知識產權,18(1),92-97。  延伸查詢new window
9.劉華美(200710)。歐盟競爭法之研發(R&D)豁免程序--對我國研發聯合管制的啟示。公平交易季刊,15(4),95-128。new window  延伸查詢new window
10.徐雅芬(2006)。全球植物藥產業概況及市場分析。農業生技產業季刊,5,1。  延伸查詢new window
11.劉育彬、黃文賢、施錫龍(200710)。淺談專利濫用。國研科技,16,73-74。  延伸查詢new window
12.Bednarek, Michael、Ineichen, Markus(200407)。Patent Pools as an Alternative to Patent Wars in Emergent Sectors。Intellectual Property & Technology Law Journal,16(7),1-5。  new window
13.Oettinger, Gerald S.(199904)。An Empirical Analysis of the Daily Labor Supply of Stadium Venors。Journal on Regulation,107(2),360-392。  new window
14.Ebersole, Ted J.、Guthrie, Marvin C.、Goldstein, Jorge A.(2005)。Patent pools and standard setting in diagnostic genetics。Nature Biotechnology,23,937-938。  new window
學位論文
1.洪萱(2008)。論我國技術授權與市場競爭之處理原則(碩士論文)。國立政治大學。  延伸查詢new window
圖書
1.汪渡村(200709)。公平交易法。臺北:五南圖書公司。  延伸查詢new window
2.廖義男(1995)。公平交易法之理論與立法。台北:三民書局。new window  延伸查詢new window
3.The US(1995)。Antitrust Guidelines for the Licensing of Intellectual Property。  new window
4.World Health Organization(2006)。Public Health, Innovation and Intellectual Property Rights。  new window
5.Clark, Jeanne et al.(0)。Patent pools: a solution to the problem of access in biotechnology patents in WHITE PAPER。United States Patent and Trademark Office。  new window
6.黃重球、經濟部. 技術處. 生醫產業技術推動辦公室(200512)。中草藥產業技術發展五年計畫90-94年總成果報告。台北市:經濟部技術處。  延伸查詢new window
7.Food and Drug Administration(2004)。Guidance for Industry Botanical Drug Products。  new window
其他
1.吳麗玲(2005)。日本競爭法對智慧財產授權行為規範之研究(C09201934)。,台北:行政院公平交易委員。  延伸查詢new window
2.李威。台灣中草藥產業面臨的困境與契機,http://www.hdais.gov.tw/04/proceedings/2009/980108/980108_3.pdf。  延伸查詢new window
3.周佰隆。台灣新興中草藥產業的科技管理,http://www.ammot.nccu.edu.tw/appear/index.php?appear_year=94。  延伸查詢new window
4.邱思緁(2008)。兩岸中草藥業啟動搭橋計畫,http://udn.com/NEWS/MAINLAND/MAI3/4617485.shtml。  延伸查詢new window
5.科技產業資訊室。能避開現有競爭者或是現有專利保護範圍之其他技術,技術追趕者的策略心法:比亞迪,http://cdnet.stpi.org.tw/techroom/analysis/2009/pat_09_A002.htm。  延伸查詢new window
6.大仁科技大學(20071122)。2007年科技中草藥國際市場行銷策略研討會資料。  延伸查詢new window
7.公平交易委員會(20010120)。(90)公處字第021號處分書。  延伸查詢new window
8.行政院公平交易委員會。行政院公平交易委員會對於技術授權協議案件之處理原則。  延伸查詢new window
9.經濟部工業局(2007)。生技新藥產業發展條例。  延伸查詢new window
10.經濟部智慧財產局(2002)。中草藥發明專利審查基準草案。  延伸查詢new window
11.Bulletin of the World Health Organization(2006)。CIPIH/WHO report。  new window
12.Gaule, Patrick(20060401)。Towards Patent Pools in Biotechnology(CEMI-REPORT-2006-010)。,University of Geneva - Faculty of Economic and Social Sciences。  new window
13.知的財産の利用に関する独占禁止法上の指針,http://hrsk.jftc.go.jp/dk/03.asp?process=0&filename=dk004010.xml&key。  延伸查詢new window
圖書論文
1.Yukio, Hiramatsu(2005)。Intellectual Property issues in standardization(Case of the ITU-T)。GRADUATE SCHOOL OF INTELLECTUAL PROPERTY。Osaka Institute of Technology。  new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
:::
無相關著作
 
QR Code
QRCODE